The firm is a collaborative drug development company with a strategic investment arm, relying on functional outsourcing to develop novel medications. The firm uses its expertise in over 110 drug development campaigns to identify exceptional companies in which to invest. The firm is interested in seed-stage therapeutics companies, frequently investing in companies recently spun out of academia, with some proof-of-concept data that are looking to hit milestones needed for a Series A raise. The firm is looking to invest in smaller rounds, with tranches of about $200-300K per year for each portfolio company. The firm will invest in companies based in North America, Europe and Israel.

The firm is interested only in companies developing small molecules or biologics. The firm will invest in companies developing new molecules, but will also consider companies developing therapeutics in the 505(b)(2) pathway. The firm is fairly agnostic to indication, with a slight preference for infectious diseases, with the exception of COVID.

The firm looks to be an active investor, taking a board observer seat, at the minimum, and looking to be involved in the development of the product. Using their expertise, the firm can help companies identify the best partners for any studies they may need to accomplish to advance their product pipeline.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A transatlantic investor founded in 2001 is based in Utrecht, the Netherlands with an additional operation in Boston, United States. The firm has raised more than €1.5 million across 3 of their most recently closed funds. The firm is currently investing from its latest fund with over €600M in committed capital. The investment size ranges from €10 million up to €60 million per portfolio company over the lifetime of the investment. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm invests in all areas of life sciences, including therapeutics, medical devices, diagnostics and digital health companies. In the past, the firm did not look at therapeutics, but is now actively investing in therapeutics companies as well. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Located in Zhengzhou, China, a venture capital firm was founded in 2018 and is the corporate venture arm of Autobio Diagnostics. Through the parent company, funding is dedicated towards early-stage life science companies from Seed to Series B. The initial size of investment is less than $50M USD and the firm aims to invest in 3-5 companies in the upcoming year. The firm is open to global opportunities.

The firm will primarily consider therapeutics and diagnostics and is open to medical devices and digital health. Within therapeutics, the firm is opportunistic and looks at technologies from Pre-clinical to Phase I. The firm has more often invested in cell and gene therapies due to interest in vaccines. Within diagnostics, all modalities from in-development to clinical phases will be considered. The firm has more often invested in in-vitro testing kits and point-of-care testing diagnostics. The firm is opportunistic in the medical devices (in-development to clinical phases) and digital health sectors. While open to all indications, the firm has a particular interest in cancer.

The firm acts as a strategic lead investor and values technology with high potential to go through the approval process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the USA  just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With about a month left until RESI Boston June 2023 and a few days before partnering launch, LSN is very excited to announce the list of 50+ finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC)!

The deadline was set earlier than our usual IPC application cycles, but the RESI team still received a record number of applications.

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition, the companies will be presenting a poster showcasing their technology in the exhibit hall. We were very impressed by all of the amazing technologies developed by the IPC finalist companies and we cannot wait to showcase them at the upcoming RESI!

Below are the participating companies. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 1,000 attendees expected to attend, you can register here!

RESI Boston June 2023 IPC Finalists

By Caitlin Dolegowski, Marketing Manager, LSN

RESI Boston, June 5-7 is rapidly approaching, and the partnering platform opens next Monday, May 15. This hybrid conference enables attendees to book meetings either in person on Monday, June 5, or virtually, June 6-7.  The LSN Partnering Platform offers startups the opportunity to search for and identify investors that are a fit for them based on sector, indication, stage of development and other criteria. Successful partnering takes a lot of work, and the companies that book the most meetings send, on average, over 100 meeting requests to relevant investors, followed by frequent follow-ups. We will be offering a free partnering tutorial next week to provide you with helpful insight into making the most of your time at RESI.

There is still time to register for RESI Boston, June 5-7 and meet with 350+ active investors in the life science industry.

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI Boston during BIO week is just a few weeks away. We’ve already told you about the opportunity to meet with 350+ investors and licensing partners and amazing panels and workshops, but you will also be able to meet with some top service providers who may have just the product or service your company needs or will need in the future. RESI is the conference for early-stage partnering, where you can make connections that are focused on this space that you won’t find at other conferences that are geared toward later stage activities.

Here are some of the companies you can meet in the RESI Exhibition Hall this June.

See you in Boston! REGISTER HERE